Document is current
Any future updates will be listed below
-
Authors
Hata, Akito https://orcid.org/0000-0001-7035-7249
Iwasawa, Shunichiro
Sasaki, Yusuke
Tajima, Kosei
Chiba, Yasutaka
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000041507 at UMIN JapanDocuments that mention this clinical trial
A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients
https://doi.org/10.1007/s12325-024-02921-x
-
Funding
Funding for this research was provided by:
Chugai Pharmaceutical
- License Information
-
More Information
Article History
Received: 30 January 2024
Accepted: 6 June 2024
First Online: 11 July 2024
Declarations
:
: Akito Hata has received speaker’s fees from Chugai Pharmaceutical Co., Ltd. Shunichiro Iwasawa, Yusuke Sasaki, and Kosei Tajima are employees of Chugai Pharmaceutical Co., Ltd. Yasutaka Chiba has no conflicts of interest.
: This study was conducted in compliance with the principles of the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects (Notification No. 1 of the Ministry of Education, Culture, Sports, Science and Technology/Ministry of Health, Labour and Welfare, dated February 28, 2017). The study was approved by the Ethical Committee of the Non-Profit Organization MINS Institutional Review Board (200220) and is registered in the UMIN Clinical Trials Registry (ID: UMIN000041507). Informed consent was not required as this is a database study using anonymized data that are devoid of any patient-identifying information per the Japanese ethical guidelines.
